MAPT and Alzheimer disease: Although a precise cause underlying AD has not yet been defined among an array of potential pathogenetic factors (Vejandla et al. 2024), such as accumulation of amyloid-β (Aβ) and hyperphosphorylated tau (p-tau) in the brain (Gulisano et al. 2018), recently, neuroinflammation has been increasingly regarded as a crucial contributor to AD pathogenesis (Leng and Edison 2021; Uddin et al. 2022; Kiraly et al. 2023).